Compare W W Grainger Inc (GWW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs TransMedics Group Inc — how do they compare? W W Grainger Inc trades at $1,289.35 (market cap $59.76B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: W W Grainger Inc is far larger — about 21.8× TransMedics Group Inc's market cap, and W W Grainger Inc pays a 0.79% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 25 Days and TransMedics Group Inc for 24 Days on average.
| GWW | TMDX | |
|---|---|---|
Market Cap | $59.76B | $2.74B |
Volume | 186,697 | 949,331 |
Sector | Industrials | Health |
52-Week High | $1.40K | $150.42 |
52-Week Low | $918.18 | $61.99 |
Typical Hold Time | 25 Days | 24 Days |
Enterprise Value | $61.96B | $3.13B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,289.79, up 2.08% today, with a bearish technical signal but strong fundamentals including a 47.92% ROE and recent earnings beats. The company reported Q2 2026 EPS of $12.01, beating expectations, and maintains a net income margin of 9.92%. Recent developments include the acquisition of technology assets from Adroit Worldwide Media for $210 million and the opening of a new distribution center in Oregon, supporting growth initiatives.
The outlook is mixed: analyst consensus is a hold with a $1,310 price target, but strong profitability and strategic acquisitions offer upside. Risks include high valuation multiples like a P/E of 32.34 and competitive pressures in industrial distribution. Cash flow trends improved in 2026, with net cash flow near breakeven, reducing liquidity concerns.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
